SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity-Reference-Cited by-同舟云学术

SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity

Published:2019-07-10 Issue:9 Volume:13 Page:1874-1886
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Liu Huiquan¹,Ertay Ayse²,Peng Ping¹,Li Juanjuan²,Liu Dian¹,Xiong Hua¹,Zou Yanmei¹,Qiu Hong¹,Hancock David³,Yuan Xianglin¹,Huang Wei‐Chien⁴⁵⁶^ORCID,Ewing Rob M.²⁷,Downward Julian³,Wang Yihua¹²⁷^ORCID

Affiliation:

1. Department of Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

2. Biological Sciences, Faculty of Environmental and Life Sciences University of Southampton UK

3. Oncogene Biology The Francis Crick Institute London UK

4. Graduate Institute of Biomedical Sciences China Medical University Taichung Taiwan

5. Center for Molecular Medicine China Medical University and Hospital Taichung Taiwan

6. Department of Biotechnology, College of Health Science Asia University Taichung Taiwan

7. Institute for Life Sciences University of Southampton UK

Funder

National Natural Science Foundation of China

Wessex Medical Research

China Medical University Hospital

Francis Crick Institute

Academy of Medical Sciences

Natural Science Foundation of Hubei Province

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12530

Reference49 articles.

1. Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

2. Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

3. Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

4. Sodium/Glucose Co-transporter 1 Expression Increases in Human Diseased Prostate

5. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy;Autoimmunity Reviews;2024-06

2. Design of Evodiamine–Glucose Conjugates with Improved In Vivo Antitumor Activity;Journal of Medicinal Chemistry;2024-04-22

3. Breast cancer therapy: from the perspective of glucose metabolism and glycosylation;Molecular Biology Reports;2024-04-20

4. Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review;Cancers;2024-04-12

5. Integrated network pharmacology and cellular assay reveal the biological mechanisms of Limonium sinense (Girard) Kuntze against Breast cancer;BMC Complementary Medicine and Therapies;2023-11-13